stockrow
Saturday 7 November 2026
Export MTNB’s income statement to Excel — free account
Matinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.
- EPS
- +79.6%
- Free cash flow
- +9.15%
- Total debt
- −54.5%
Quarter to June 2026, against a year earlier
1.19
0.03
+2.59%
Follow MTNB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.60 | 1.15 | 2.77 | 3.67 | |
Current Ratio |
0.85 | 1.32 | 2.79 | 3.78 | |
Net Debt/EBITDA |
0.52 | 1.31 | 2.69 | 3.73 | |
Debt/Assets |
0.15% | 0.09% | 0.07% | 0.11% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.38 | 0.83 | 0.79 | 0.69 | |
Capex/Depreciation |
0.00 | 0.00 | 0.16 | 2.88 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.30) | (3.75) | (4.13) | (4.07) | |
Capex per Share |
0.00 | 0.00 | 0.04 | 0.88 | |
Free Cash Flow per Share |
(4.30) | (3.75) | (4.09) | (3.18) | |
Cash per Share |
1.90 | 5.73 | 11.09 | 15.13 | |
Shareholders Equity per Share |
4.21 | 7.07 | 13.23 | 17.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.21 | 7.07 | 13.23 | 17.82 | |
Free Cash Flow |
(1.84) | (1.60) | (1.49) | (1.15) | |
Working Capital |
(0.21) | 0.69 | 2.61 | 4.16 | |
Capital Expenditures |
— | — | 0.02 | 0.32 | |
Net Current Asset Value |
(0.47) | (0.04) | 1.70 | 2.42 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.51 | 0.50 | 0.21 | 0.21 | |
Average Assets |
7.42 | 8.95 | 9.92 | 15.14 | |
Average Common Equity |
4.74 | 4.65 | 6.21 | 11.12 |
Columns are period end dates · fundamentals updated 2 Nov 2026